MTHFR polymorphisms' influence on outcome and toxicity in acute lymphoblastic leukemia patients

Leukemia Research

Volumn 31, Issue 12, 2007, Pages 1669-1674

  Chiusolo, Patrizia ^a   Reddiconto, Giovanni ^a   Farina, Giuliana ^a   Mannocci, Alice ^a   Fiorini, Alessia ^b   Palladino, Mariangela ^a   La Torre, Giuseppe ^a   Fianchi, Luana ^a   Sorà, Federica ^a   Laurenti, Luca ^a   Leone, Giuseppe ^a   Sica, Simona ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b NONE

Author keywords

ALL; MTHFR; Outcome; Polymorphisms; Toxicity

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME POLYMORPHISM; FEMALE; GENOTYPE; HOMOZYGOSITY; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UNIVARIATE ANALYSIS; WILD TYPE;

ADOLESCENT; ADULT; AGED; CHILD; DRUG TOXICITY; FEMALE; GENOTYPE; HUMANS; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POINT MUTATION; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 35748970501     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.03.028     Document Type: Article

References (25)

1. Pui C.H., and Evans W.E. Treatment of acute lymphoblastic leukemia. NEJM 354 (2006) 166-178
2. Thomas X., and Le Q.H. Prognostic factors in adult acute lymphoblastic leukaemia. Hematology 8 (2003) 233-242
3. Nachman J. Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia. Br J Haematol 130 (2005) 166-173
4. Cheok M.H., and Evans W.E. Acute lymphoblastic leukemia: a model for the pharmacogenomics of cancer therapy. Nat Rev 6 (2006) 117-129
5. Bailey L.B., and Gregory J.P. Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. J Nutr 129 (1999) 919-922
6. Ueland P.M., Hustad S., Schneede J., et al. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 22 (2001) 195-201
7. Weisberg I., Tran P., Christensen B., et al. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metabol 64 (1998) 169-172
8. De Stefano V., Chiusolo P., Paciaroni K., et al. Prevalence of the 677C to T mutation in the methylenetetrahydrofolate reductase gene in Italian patients with venous thrombotic disease. Thromb Haemost 79 (1998) 686-687
9. Papa A., De Stefano V., Danese S., et al. Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease. Am J Gastroenterol 96 (2001) 2677-2682
10. Robien K., and Ulrich C.M. 5,10-Methyletetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE minireview. Am J Epidemiol 157 (2003) 571-582
11. Skibola C.F., Smith M.T., Kane E., et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukaemia in adults. Proc Natl Acad Sci USA 96 (1999) 12810-12815
12. Krajinovic M., Lamothe S., Labuda D., et al. Role of the MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukaemia. Blood 103 (2004) 252-257
13. Chiusolo P., Reddiconto G., Cimino G., et al. Methylenetetrahydrofolate reductase genotypes do not play a role in acute lymphoblastic leukemia pathogenesis in the Italian population. Haematologica 89 (2004) 139-144
14. Franco R.F., Simoes B.P., Tone L.G., et al. The methylenetetrahydrofolate reductase C677T gene polymorphism decrease the risk of childhood acute lymphocytic leukaemia. Br J Haematol 115 (2001) 616-618
15. Thirumaran R.K., Gast A., Flohr T., et al. MTHFR genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukaemia. Blood 106 (2005) 2590-2591
16. Chiusolo P., Reddiconto G., Casorelli I., et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 13 (2002) 1915-1918
17. Annino L., Vegna M.L., Camera A., et al. Treatment of adult acute lymphoblastic leukemia (ALL): long term follow-up of the GIMEMA ALL 0288 randomized study. Blood 99 (2002) 863-871
18. Magrath I.T. Management of high-grade lymphomas. Oncology 12 (1998) 40-48
19. Frosst P., Blom H.J., Milos R., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10 (1995) 111-113
20. Aplenc R., Thompson J., Han P., et al. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 65 (2005) 2482-2487
21. Krajinovic M., Lemieux-Blanchard E., Chiasson S., et al. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukaemia. Pharmacogenom J 4 (2004) 66-72
22. Shimasaki N., Mori T., Samejima H., et al. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatric Hematol Oncol 28 (2006) 64-68
23. Ulrich C.M., Yasui Y., Storb R., et al. Pharmacogenetics of methotrexate: toxicity among transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98 (2001) 231-234
24. Toffoli G., Russo A., Innocenti F., et al. Effect of methylenetetrahydrofolate reductase 677CT polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 103 (2003) 294-299
25. Urano W., Taniguchi A., Yamanaka H., et al. Polymorphisms in the methylenetetrahydrofolate gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12 (2002) 183-190